Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients

Journal of Immunology

Volumn 179, Issue 8, 2007, Pages 5238-5245

  Nozaki, Taiji ^a,c   Amano, Hiroyuki ^a,c   Bickerstaff, Alice ^d   Orosz, Charles G ^d   Novick, Andrew C ^a   Tanabe, Kazunari ^c   Fairchild, Robert L ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; CHEMOKINE RECEPTOR CCR5; GAMMA INTERFERON; INTERLEUKIN 4; RAG1 PROTEIN; ALLOANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CARDIAC GRAFT REJECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; GRAFT RECIPIENT; HEART GRAFT; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; WILD TYPE; A J MOUSE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; COMPARATIVE STUDY; GENETICS; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTOPENIA; METABOLISM; MOUSE MUTANT; PASSIVE IMMUNIZATION; PATHOLOGY; PHYSIOLOGY; TRANSPLANTATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GRAFT ENHANCEMENT, IMMUNOLOGIC; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNE SERA; IMMUNIZATION, PASSIVE; ISOANTIBODIES; LYMPHOCYTE ACTIVATION; LYMPHOPENIA; MALE; MICE; MICE, INBRED A; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, CCR5;

EID: 38449105267     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.8.5238     Document Type: Article

References (43)

1. Colvin, R. B., and R. N. Smith. 2005. Antibody-mediated organ-allograft rejection. Nat. Rev. Immunol. 5: 807-817.
2. Racusen, L. C., R. B. Colvin, K. Solez, M. J. Mihatsch, P. F. Halloran, P. M. Campbell, M. J. Cecka, J.-P. Cosyns, A. J. Demetris, M. C. Fishbein, et al. 2003. Antibody-mediated rejection criteria: an addition to the Banff '97 classification of renal allograft rejection. Am. J. Transplant. 3: 708-714.
3. Takemoto, S. K., A. Zeevi, S. Feng, R. B. Colvin, S. Jordan, J. Kobashigawa, J. Kupiec-Weglinski, A. Matas, R. A. Montgomery, P. Nickerson, et al. 2004. National conference to assess antibody-mediated rejection in solid organ transplantation. Am. J. Transplant. 4: 1033-1041.
4. George, J. F., J. K. Kirklin, T. W. Shroyer, D. C. Naftel, R. C. Bourge, D. C. McGiffin, C. White-Williams, and T. Noreuil. 1995. Utility of posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients. J. Heart Lung Transplant. 14: 856-864.
5. Smith, J. D., A. J. Danskine, and M. L. Rose. 1992. Specificity of lymphocytotoxic antibodies formed after cardiac transplantation and correlation with rejection episodes. Transplantation 53: 1358-1362.
6. McKenna, R. M., S. K. Takemoto, and P. I. Terasaki. 2000. Anti-HLA antibodies after solid organ transplantation. Transplantation 69: 319-326.
7. Terasaki, P. I. 2003. Humoral theory of transplantation. Am. J. Transplant. 3: 665-673.
8. Rodriguez, E. R., D. V. Skojec, C. D. Tan, A. A. Zachary, E. K. Kasper, J. V. Conte, and W. M. Baldwin. 2005. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am. J. Transplant. 5: 2778-2785.
9. Smith, R. N., N. Brousaides, L. Grazette, S. Saidman, M. Semigran, T. Disalvo, J. Madsen, G. W. Dee, A. R. Perez-Atayde, and A. B. Collins. 2005. C4d deposition in cardiac allografts correlates with alloantibody. J. Heart Lung Transplant. 24: 1202-1210.
10. Collins, A. B., E. E. Schneeberger, M. A. Pascual, S. L. Saidman, W. W. Williams, N. Tolkoff-Rubin, A. B. Cosimi, and R. B. Colvin. 1999. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J. Am. Soc. Nephrol. 10: 2208-2214.
11. Feucht, H. E., and M. J. Mihatsch. 2005. Diagnostic value of C4d in renal biopsies. Curr. Opin. Nephrol. Hypertens. 14: 592-598.
12. Feucht, H. E., H. Schneeberger, G. Hillebrand, K. Burkhardt, M. Weiss, G. Riethmuller, W. Land, and E. Albert. 1993. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int. 43: 1333-1338.
13. Reed, E. F., A. J. Demetris, E. Hammond, S. Itescu, J. A. Kobashigawa, N. L. Reinsmoen, E. R. Rodriguez, M. Rose, S. Stewart, N. Sucia-Foca, et al. 2006. Acute antibody-mediated rejection of cardiac transplants. J. Heart Lung Transplant. 25: 153-159.
14. Halloran, P. F., J. Schlaut, K. Solez, and N. S. Srinivasa. 1992. The significance of the anti-class I antibody response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 53: 550-555.
15. Lobo, P. I., C. E. Spencer, W. C. Stevenson, and T. L. Pruett. 1995. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin. Transplantation 59: 357-360.
16. El-Sawy, T., N. M. Fahmy, and R. L. Fairchild. 2002. Chemokines: directing leukocyte infiltration into allografts. Curr. Opin. Immunol. 14: 562-568.
17. Hancock, W. W. 2003. Chemokine receptor-dependent alloresponses. Immunol. Rev. 196: 37-50.
18. Gao, W., K. L. Faia, V. Csizmadia, S. T. Smiley, D. Soler, J. A. King, T. M. Danoff, and W. W. Hancock. 2001. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 72: 1199-1205.
19. Hancock, W. W., B. Lu, W. Gao, V. Csizmadia, K. Faia, J. A. King, S. T. Smiley, M. Ling, N. P. Gerard, and C. Gerard. 2000. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J. Exp. Med. 192: 1515-1520.
20. Amano, H., A. Bickerstaff, C. G. Orosz, A. C. Novick, H. Toma, and R. L. Fairchild. 2005. Absence of recipient CCR5 promotes early and increased allospecific antibody responses to cardiac allografts. J. Immunol. 174: 6499-6508.
21. Corry, R. J., H. J. Winn, and P. S. Russell. 1973. Primarily vascularized allografts of hearts in mice. Transplantation 1973: 343-350.
22. El-Sawy, T., J. A. Belperio, R. M. Strieter, D. G. Remick, and R. L. Fairchild. 2005. Inhibition of polymorphonuclear leukocyte-mediated graft damage synergizes with short-term costimulatory blockade to prevent cardiac allograft rejection. Circulation 112: 320-331.
23. Hall, B. 1991. Cells mediating allograft rejection. Transplantation 51: 51-62.
24. Rosenberg, A. S., and A. Singer. 1993. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Annu. Rev. Immunol. 10: 333-358.
25. Brandle, D., J. Joergensen, G. Zenke, K. Burki, and R. P. Hof. 1998. Contribution of donor-specific antibodies to acute allograft rejection: evidence from B cell-deficient mice. Transplantation 65: 1489-1493.
26. Wasowska, B. A., Z. Qian, D. L. Cangello, E. Behrens, K. van Tran, J. Layton, F. Sanfilippo, and W. M. Baldwin. 2001. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation 71: 727-736.
27. Halloran, P. F., J. Schlaut, K. Solez, and N. S. Srinivasa. 1992. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 53: 550-555.
28. Qian, Z., C.-Y. Lee, K. Murata, J. Liu, K. Fox-Talbot, B. A. Wasowska, and W. M. Baldwin. 2006. Antibody and complement mediated injury in transplants following sensitization by allogeneic blood transfusion. Transplantation 82: 857-864.
29. Rahimi, S., Z. Qian, J. Layton, K. Fox-Talbot, W. M. Baldwin, and B. A. Wasowska. 2004. Non-complement- and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am. J. Transplant. 4: 326-334.
30. Baggiolini, M., B. Dewald, and B. Moser. 1994. Interleukin-8 and related chemotactic cytokines: CXC and CC chemokines. Adv. Immunol. 55: 97-179.
31. Baggiolini, M., A. Walz, and S. L. Kunkel. 1989. Neutrophil-activating peptide-1/interleukin-8, a novel cytokine that activates neutrophils. J. Clin. Invest. 84: 1045-1049.
32. Brauer, R. B., W. M. Baldwin, S. Ibrahim, and F. Sanfilippo. 1995. The contribution of terminal complement components to acute and hyperacute allograft rejection in the rat. Transplantation 59: 288-293.
33. Nakashima, S., Z. Qian, S. Rahimi, B. A. Wasowska, and W. M. Baldwin. 2002. Membrane attack complex contributes to destruction of vascular integrity in acute lung allograft rejection. J. Immunol. 169: 4620-4627.
34. Qian, Z., F. M. Jakobs, T. Pfaff-Amesse, F. Sanfilippo, and W. M. Baldwin. 1998. Complement contributes to the rejection of complete and class I major histocompatibility complex-incompatible cardiac allografts. J. Heart Lung Transplant. 17: 470-478.
35. He, C., S. Schenk, Q. Zhang, A. Valujskikh, J. Bayer, R. L. Fairchild, and P. S. Heeger. 2004. Effects of T cell frequency and graft size on transplant outcome in mice. J. Immunol. 172: 240-247.
36. Jones, N. D., S. E. Turvey, A. Van Maurik, M. Hara, C. I. Kingsley, C. H. Smith, A. L. Mellor, P. J. Morris, and K. J. Wood. 2001. Differential susceptibility of heart, skin, and islet allografts to T cell-mediated rejection. J. Immunol. 166: 2824-2830.
37. Chen, Z., S. Cobbold, S. Metcalfe, and H. Waldmann. 1992. Tolerance in the mouse to major histocompatibility complex-mismatched heart allografts, and to rat heart xenografts, using monoclonal antibodies to CD4 and CD8. Eur. J. Immunol. 22: 805-810.
38. Cobbold, S. P., A. Jayasuriya, A. Nash, T. D. Propero, and H. Waldmann. 1984. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312: 548-551.
39. + cells are essential for allorejection. J. Exp. Med. 184: 2013-2018.
40. Abdi, R., R. N. Smith, L. Makhlouf, N. Najafian, A. D. Luster, H. Auchincloss, and M. H. Sayegh. 2002. The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes 51: 2489-2495.
41. Carvalho-Pinto, C., M. I. Garcia, L. Gomez, A. Ballesteros, A. Zaballos, J. M. Flores, M. Mellado, J. M. Rodriguez-Frade, D. Balomenos, and C. Martinez-A. 2004. Leukocyte attraction through the CCR5 receptor controls progress from insulitis to diabetes in non-obese diabetic mice. Eur. J. Immunol. 34: 548-557.
42. + regulatory T cells during acute graft-versus-host disease. Blood 106: 3300-3307.
43. + regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J. Exp. Med. 203: 2451-2460.